Darovasertib data are promised for the last week of March.
ApexOnco Front Page
Recent articles
Just like other oral SERDs, filing is restricted to the ESR1-mutant population.
The group is keeping faith with the novel target KLK2.
Dreamm-8 is heralded as marking doctors’ ability to deal better with Blenrep’s toxicities.
But toxicity could hold back Destiny-Breast06's ability to change clinical practice.
Fears that Adriatic’s statistical survival wins would be clinically marginal haven’t materialised.
Tagrisso is a knockout on PFS, but only OS will show whether it should be given before patients progress.
The company’s pivotal trial is now set to start in the second half of 2025, from year-end 2024 previously.